These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 23507703

  • 1. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
    Gravina GL, Marampon F, Muzi P, Mancini A, Piccolella M, Negri-Cesi P, Motta M, Lenzi A, Di Cesare E, Tombolini V, Jannini EA, Festuccia C.
    Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
    [Abstract] [Full Text] [Related]

  • 2. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC.
    Prostate; 2010 Feb 01; 70(2):179-89. PubMed ID: 19790234
    [Abstract] [Full Text] [Related]

  • 3. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
    McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP.
    Prostate; 2018 Mar 01; 78(4):266-277. PubMed ID: 29243324
    [Abstract] [Full Text] [Related]

  • 4. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.
    Int J Oncol; 2015 Apr 01; 46(4):1560-72. PubMed ID: 25634071
    [Abstract] [Full Text] [Related]

  • 5. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M, Iljin K, Halonen P, Sara H, Kaivanto E, Nees M, Kallioniemi OP.
    Int J Cancer; 2008 Dec 15; 123(12):2774-81. PubMed ID: 18798265
    [Abstract] [Full Text] [Related]

  • 6. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
    Ai J, Wang Y, Dar JA, Liu J, Liu L, Nelson JB, Wang Z.
    Mol Endocrinol; 2009 Dec 15; 23(12):1963-72. PubMed ID: 19855091
    [Abstract] [Full Text] [Related]

  • 7. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.
    Mol Cancer Ther; 2013 Nov 15; 12(11):2342-55. PubMed ID: 23966621
    [Abstract] [Full Text] [Related]

  • 8. Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
    Gravina GL, Marampon F, Piccolella M, Biordi L, Ficorella C, Motta M, Jannini EA, Tombolini V, Festuccia C.
    Prostate; 2011 Oct 01; 71(14):1481-91. PubMed ID: 21446006
    [Abstract] [Full Text] [Related]

  • 9. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM, Carter SL, Gillis JL, Marrocco-Tallarigo DL, Grose RH, Tilley WD, Butler LM.
    Endocr Relat Cancer; 2015 Oct 01; 22(5):805-18. PubMed ID: 26187127
    [Abstract] [Full Text] [Related]

  • 10. Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-κB and HSP90 in castration resistant prostate cancer.
    Kim Y, Park SE, Moon JW, Kim BM, Kim HG, Jeong IG, Yoo S, Ahn JB, You D, Pak JH, Kim S, Hwang JJ, Kim CS.
    Prostate; 2017 Jul 01; 77(10):1128-1136. PubMed ID: 28556958
    [Abstract] [Full Text] [Related]

  • 11. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R, Chen B, Patki M, McFall T, Ou S, Heath E, Ratnam M, Qin Z.
    Mol Pharmacol; 2016 Sep 01; 90(3):225-37. PubMed ID: 27382012
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL, Marampon F, Giusti I, Carosa E, Di Sante S, Ricevuto E, Dolo V, Tombolini V, Jannini EA, Festuccia C.
    Int J Oncol; 2012 Mar 01; 40(3):711-20. PubMed ID: 22134754
    [Abstract] [Full Text] [Related]

  • 13. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M, Kimura T, Kamata Y, Tashiro K, Kimura S, Koike Y, Sato S, Yorozu T, Furusato B, Takahashi H, Kiyota H, Egawa S.
    Prostate; 2019 Jun 01; 79(9):1043-1052. PubMed ID: 30998834
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines.
    Schütz SV, Cronauer MV, Rinnab L.
    J Cell Biochem; 2010 Apr 15; 109(6):1192-200. PubMed ID: 20127713
    [Abstract] [Full Text] [Related]

  • 15. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, Lee SJ.
    J Clin Endocrinol Metab; 2015 Feb 15; 100(2):E253-61. PubMed ID: 25389633
    [Abstract] [Full Text] [Related]

  • 16. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ.
    J Cell Biochem; 2010 Aug 01; 110(5):1187-94. PubMed ID: 20589722
    [Abstract] [Full Text] [Related]

  • 17. Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
    Jadhavar PS, Ramachandran SA, Riquelme E, Gupta A, Quinn KP, Shivakumar D, Ray S, Zende D, Nayak AK, Miglani SK, Sathe BD, Raja M, Farias O, Alfaro I, Belmar S, Guerrero J, Bernales S, Chakravarty S, Hung DT, Lindquist JN, Rai R.
    Bioorg Med Chem Lett; 2016 Nov 01; 26(21):5222-5228. PubMed ID: 27717544
    [Abstract] [Full Text] [Related]

  • 18. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V, Menon M, Thamilselvan S.
    Int J Cancer; 2016 Oct 01; 139(7):1632-47. PubMed ID: 27198552
    [Abstract] [Full Text] [Related]

  • 19. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
    Sun H, Mediwala SN, Szafran AT, Mancini MA, Marcelli M.
    Horm Cancer; 2016 Jun 01; 7(3):196-210. PubMed ID: 26957440
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of glycogen synthase kinase-3β counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer.
    Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M.
    PLoS One; 2011 Jun 01; 6(9):e25341. PubMed ID: 21980429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.